Eleanya Ogburu-Ogbonnaya, MD
Neurology · Columbia, SCNPI 1104005941
Payments from drug & device makers
Across 692 payments — averaging $197.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$61K
- Lexicon Pharmaceuticals, Inc.$25K
- AbbVie$21K
- Indivior Inc.$12K
- E.r. Squibb & Sons, L.L.C.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- plus $13K from 54 others
What the payments were for
- Speaking & faculty fees$19,09053%
- Travel & lodging$4,37212%
- Food & beverage$12,53135%
- Education$2321%
- Gifts$00%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$20,176
- Prolate$1,542
- Prometra II$1,372
- VNS - Sentiva$1,320
- PROCLAIM$998
- Nalocet$619
- GOCOVRI$169
- TANLOR$150
- AUSTEDO$138
- Austedo XR$131
- AIMOVIG$122
- ULTOMIRIS$100
How this compares
$136,647 in reported general payments places this provider in the 90th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 633 | $337,598 |
| OxycontinOxycodone Hcl | 321 | $196,757 |
| Nurtec OdtRimegepant Sulfate | 106 | $189,518 |
| Austedo XrDeutetrabenazine | 29 | $181,120 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 2,673 | $173,882 |
| OzempicSemaglutide | 163 | $160,863 |
| LinzessLinaclotide | 264 | $157,278 |
| IngrezzaValbenazine Tosylate | 17 | $146,013 |
| CopaxoneGlatiramer Acetate | 18 | $99,050 |
| MounjaroTirzepatide | 70 | $71,920 |
| VraylarCariprazine Hcl | 48 | $70,674 |
| UbrelvyUbrogepant | 50 | $64,355 |
| Dimethyl Fumarate | 33 | $56,580 |
| ProlateOxycodone Hcl/Acetaminophen | 17 | $41,805 |
| TrulancePlecanatide | 60 | $36,819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er | $687 | $357,170646 claims |
| AbbVieLinzess, Vraylar, Ubrelvy, Botox, Qulipta | $21,193 | $333,556396 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Copaxone | $1,527 | $280,17047 claims |
| PfizerNurtec Odt | $556 | $189,518106 claims |
| Novo NordiskOzempic, Rybelsus | $131 | $177,380180 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $609 | $146,01317 claims |
| Forte Bio-pharma LLCProlate | $1,150 | $41,80517 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $77 | $36,81960 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $384 | $27,73850 claims |
| Eisai Inc.Fycompa | $587 | $25,31524 claims |
| Amneal Pharmaceuticals LLCRytary | $234 | $13,12421 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $53 | $9,57284 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 270 neurology providers in South Carolina.
Other neurology in Columbia
- William McElveenColumbia$3.7M
- Joseph FerraraColumbia$99K
- David HammettColumbia$86K
- Davit MrelashviliColumbia$70K
- Pradeep BolluColumbia$55K
- Miroslav CuturicColumbia$27K
- Mary HughesGreenville$6.3M
- Robert CarlileSummerville$2.3M
- Andrew KeeganCharleston$2.2M
- Paul MazzeoPort Royal$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.